Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy

William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating on June 4.

Sami Corwin’s rating is based on Arcellx Inc’s promising commercial launch preparations and the potential market opportunity for its anito-cel therapy in treating relapsed/refractory multiple myeloma. The company, in collaboration with Kite, is preparing to capture a significant share of the fourth-line and later market upon launch, with plans to expand to all 4L+ patients by 2027, targeting a global market potential of over 24,000 doses.
Additionally, the manageable safety profile of anito-cel, as highlighted by key opinion leaders, sets it apart from existing therapies, which face challenges such as toxicities. This differentiation, alongside the anticipated growth of the global multiple myeloma CAR-T market to approximately $12 billion by 2028, supports the Buy rating, as Arcellx is well-positioned to capitalize on these opportunities.

According to TipRanks, Corwin is a 2-star analyst with an average return of 0.8% and a 41.67% success rate. Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Allogene Therapeutics, and Arcellx Inc.

In another report released on June 4, Barclays also maintained a Buy rating on the stock with a $115.00 price target.